Calidi Biotherapeutics, Inc. (NYSEAMERICAN:CLDI) Short Interest Update

Calidi Biotherapeutics, Inc. (NYSEAMERICAN:CLDI) was the recipient of a significant decline in short interest in the month of December. As of December 15th, there was short interest totaling 71,326 shares, a decline of 28.7% from the November 30th total of 100,053 shares. Currently, 1.1% of the company’s shares are sold short. Based on an average daily volume of 66,726 shares, the days-to-cover ratio is currently 1.1 days. Based on an average daily volume of 66,726 shares, the days-to-cover ratio is currently 1.1 days. Currently, 1.1% of the company’s shares are sold short.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Armistice Capital LLC purchased a new position in Calidi Biotherapeutics during the 1st quarter worth $1,881,000. Belpointe Asset Management LLC bought a new position in shares of Calidi Biotherapeutics during the 1st quarter worth $141,000. Finally, Warberg Asset Management LLC bought a new position in shares of Calidi Biotherapeutics during the 3rd quarter worth $28,000. Institutional investors own 12.53% of the company’s stock.

Calidi Biotherapeutics Stock Performance

Shares of NYSEAMERICAN CLDI traded up $0.02 during mid-day trading on Wednesday, reaching $1.17. The company had a trading volume of 130,169 shares, compared to its average volume of 479,876. Calidi Biotherapeutics has a 52 week low of $1.10 and a 52 week high of $19.20. The business’s 50-day moving average is $1.44 and its 200-day moving average is $2.87. The company has a current ratio of 2.12, a quick ratio of 2.12 and a debt-to-equity ratio of 0.11.

Calidi Biotherapeutics (NYSEAMERICAN:CLDI) last released its quarterly earnings data on Thursday, November 13th. The company reported ($2.21) earnings per share (EPS) for the quarter. Analysts expect that Calidi Biotherapeutics will post -4.48 earnings per share for the current fiscal year.

About Calidi Biotherapeutics

Calidi Biotherapeutics is a clinical-stage biotechnology company focused on the development of targeted immunotherapies that harness the body’s innate immune system to treat cancer and infectious diseases. By delivering proprietary RNA-based immune stimulants directly into the tumor microenvironment or sites of infection, Calidi aims to trigger a robust local immune response while minimizing systemic toxicity. The company’s platform is designed to engage multiple innate immune pathways, including toll-like receptors and RIG-I-like receptors, to initiate durable antitumor and antiviral activity.

Calidi’s lead oncology programs include CB-012, an intravesical therapy in clinical development for non-muscle invasive bladder cancer, and CB-013, an intratumoral candidate targeting a range of advanced solid tumors.